O'Donnell PH, Arkenau HT, Sridhar SS, et al. - Given that a meaningful clinical activity of durvalumab in patients with metastatic urothelial carcinoma (mUC) has been reported in Study 1108, researchers undertook this inquiry to explore patient-reported outcomes (PROs) from Study 1108 as well as their link with inflammatory biomarkers. Using the Functional Assessment of Cancer Therapy–Bladder and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, the evaluation of disease-related symptoms, functioning, and health-related quality of life (HRQOL) was done. Findings revealed improvements in disease-associated symptoms, functioning, and HRQOL in correlation with durvalumab treatment in patients with mUC. A possible contribution of improvements in systemic inflammation to PRO improvements was suggested.